Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Starting soon · Phase 3

Conditions studied: B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

In brief

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.

Key facts

Study ID

NCT07516093

Run by

Nurix Therapeutics, Inc.

People needed

620

Starts

2026-06-01

Expected to finish

2032-06-01

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.